Skip to main content

Dicerna Issued Notice of Allowance on Dicer-Substrate Technology

Premium

Dicerna Pharmaceuticals said this week that the US Patent and Trademark Office has issued the company a notice of allowance for a patent application covering its core Dicer-substrate technology.

Dicerna did not provide specific details about the intellectual property, but said that the new allowance “applies to 148 claims and provides exclusivity around both in vivo therapeutic and in vitro uses of Dicer-substrates for reducing mammalian target gene expression, regardless of their specific sequence.”

Developed by researchers at the City of Hope and Integrated DNA Technologies, Dicer-substrates are essentially synthetic RNA duplexes around 27 nucleotides long. In animal studies, they have been shown to be more potent than standard 21-mer siRNAs while avoiding immune stimulation.

Dicerna was founded in 2007 to develop the technology for therapeutic applications (GSN 11/8/2007).

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.